Handelsavisen
prelaunch
Companies Healthcare 7061.T
70
7061.T Tokyo Stock Exchange Healthcare Facilities & Services

Japan Hospice Holdings Inc

¥556,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
4,7B JPY
P/E
19,4x
EV / Rev
1,0x
Div yield
3,36 %
Op margin
9,8 %
ROE
5,2 %
Net margin
5,6 %
Debt / equity
3,69
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Japan Hospice Holdings Inc provides hospice and palliative care services in Japan, generating revenue primarily through patient care and related healthcare services.

Business. Japan Hospice Holdings Inc (7061.T) is a healthcare services company primarily engaged in the operation of hospice and palliative care facilities. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
19,4x
P/E
Analysts
not yet wired
Ownership
not yet wired
Profitability
5,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 7061.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 7061.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Japan Hospice Holdings Inc (7061.T) is a healthcare services company primarily engaged in the operation of hospice and palliative care facilities. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    Japan Hospice Holdings Inc has a market price of 639 JPY per share, with a market capitalization of 5,399,939,790 JPY. The company's price-to-earnings ratio is 35.52, and its price-to-book ratio is 1.85, indicating a moderate premium over book value. The enterprise value to EBITDA ratio is 54.81, suggesting a high valuation relative to earnings before interest, taxes, depreciation, and amortization. The company's liquidity position is characterized by a current ratio of 1.93, which is above 1, indicating that it can cover its short-term liabilities with its short-term assets.

    In terms of profitability, the company's return on equity is 5.2%, and its return on assets is 1.01%, both of which are below the industry median for Healthcare Facilities & Services. The company's operating income margin is 9.83%, and its net income margin is 5.58%, which are also below the industry median. The company's debt-to-equity ratio is 3.69, indicating a high level of leverage, which is a concern given the industry's preference for lower debt levels.

    The company's revenue is concentrated in Japan, with no disclosed geographic diversification. The company operates in a single business segment, which is hospice and palliative care services. This lack of diversification increases the company's exposure to local market conditions and regulatory changes.

    Looking at the company's growth trajectory, the current fiscal year is expected to see a revenue increase of 11.5% compared to the previous year. The next fiscal year is projected to see a revenue increase of 10.2%. Analysts have estimated a mean EPS of 39.20 JPY for the current fiscal year, compared to the last actual EPS of 33.08 JPY. The company's revenue is expected to grow from 14,168,930,000 JPY to 15,800,000,000 JPY in the current fiscal year.

    The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag is that the company's net cash is negative after subtracting total debt, which is a concern for liquidity. The company's debt-to-equity ratio of 3.69 is high, and the company has a significant amount of long-term debt, which could impact its financial flexibility. The company's dilution risk is low, as there is no indication of significant dilution potential in the near term.

    Recent events include the company's financial performance and analyst estimates. The company's last actual revenue was 14,168,930,000 JPY, and the mean revenue estimate for the current fiscal year is 15,800,000,000 JPY. The company's last actual EPS was 33.08 JPY, and the mean EPS estimate for the current fiscal year is 39.20 JPY. These figures indicate that the company is expected to outperform its previous performance in terms of both revenue and earnings per share.

    Key takeaways
    • Japan Hospice Holdings Inc has a high debt-to-equity ratio of 3.69, indicating a high level of leverage.
    • The company's return on equity is 5.2%, and its return on assets is 1.01%, both of which are below the industry median.
    • The company's revenue is concentrated in Japan, with no disclosed geographic diversification.
    • The company is expected to see a revenue increase of 11.5% in the current fiscal year and 10.2% in the next fiscal year.
    • The company's liquidity position is characterized by a current ratio of 1.93, which is above 1, indicating that it can cover its short-term liabilities with its short-term assets.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Revenue grew at a 23.9% CAGR over four years, demonstrating strong top-line expansion momentum.

    Return on equity of 5.2% surpasses the 4.6% median, showing better capital efficiency than peers.

    Free cash flow improved by 13.3% year-over-year, suggesting a recovery in cash generation capabilities.

    BEAR CASE · 3

    Debt-to-equity ratio of 3.69 sits in the bottom quartile, indicating excessive leverage compared to peers.

    The company faces high credit risk, raising concerns about its ability to meet financial obligations.

    Free cash flow turned negative at -1.68 billion JPY, highlighting ongoing cash burn issues.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-13
    Q4 2025 · Quarter highlights

    Revenue ¥3.81B, +17,5% YoY; Operating income −56,7% YoY.

    Revenue¥3.81B+17,5 % YoY
    Operating income¥148.1M−56,7 % YoY
    Net income-¥26.3M−113,0 % YoY
    Free cash flow
    EPS
    Operating cash flow¥1.05B+25,2 % YoY
    Financials
    Income statement
    Revenue¥3.81B
    Gross profit¥517.6M
    Operating income¥148.1M
    Net income-¥26.3M
    Margins
    Gross margin13.6%
    Operating margin3.9%
    Net margin-0.7%
    FCF margin
    Balance sheet
    Total assets¥18.92B
    Total liabilities¥15.25B
    Total equity¥3.68B
    Cash & equivalents¥2.01B
    Long-term debt¥13.18B
    Cash flow
    Operating cash flow¥1.05B
    CapEx-¥2.41B
    Free cash flow
    SBC
    P&L flow · revenue → net income
    Revenue ¥3.81BOperating costs ¥3.66BTax ¥174.5MNet income ¥26.3M
    Highlights
    • Revenue ¥3.81B, +17,5% YoY
    • Operating income −56,7% YoY
    • Net income −113,0% YoY
    • Net margin -0.7%

    Valuation TTM

    Market price
    ¥556,00
    Market cap
    ¥5.40B
    Enterprise value
    ¥14.69B
    P/E
    19.4x
    Non-GAAP P/E
    EV / Revenue
    1.0x
    EV / Op income
    17.2x
    EV / OCF
    P / B
    1.9x
    P / Tangible book
    1.9x
    Tangible book
    ¥2.92B
    Net cash
    -¥9.29B
    Current ratio
    1.9
    Debt / equity
    3.7
    ROA
    1.0%
    ROE
    5.2%
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    39,20
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate39,20
    Revenueno estimateno estimate15,8B JPY
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in JPY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data
    EPS surprise
    −15,6 %
    reported vs consensus · miss
    Revenue surprise
    −10,3 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin9,8 %Above median
    Net Margin5,6 %Above median
    ROE5,2 %Above median
    D/E3,69Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Japan Hospice Holdings Inc Market data — financials · 2026-05-27
    • Japan Hospice Holdings Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    7061.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    PredictorBeat prob45 %Surprise0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-02-13 12:00 UTCEARNINGSQuarterly results — Q4 2025 Revenue JPY 3.81B · Net JPY -26.3M
    2026-02-13 12:00 UTCEARNINGSAnnual results — FY 2026 Revenue JPY 14.17B · Net JPY 278.0M
    2025-11-14 12:00 UTCEARNINGSQuarterly results — Q3 2025 Revenue JPY 3.67B · Net JPY 188.7M
    2025-08-13 08:43 UTCEARNINGSQuarterly results — Q2 2025 Revenue JPY 3.46B · Net JPY 60.6M
    2025-05-09 12:12 UTCEARNINGSQuarterly results — Q1 2025 Revenue JPY 3.24B · Net JPY 55.0M
    2025-02-13 12:00 UTCEARNINGSQuarterly results — Q4 2024 Revenue JPY 3.24B · Net JPY 202.0M
    2025-02-13 12:00 UTCEARNINGSAnnual results — FY 2025 Revenue JPY 12.12B · Net JPY 639.6M
    2024-11-14 12:00 UTCEARNINGSQuarterly results — Q3 2024 Revenue JPY 3.19B · Net JPY 212.6M
    2024-08-13 11:30 UTCEARNINGSQuarterly results — Q2 2024 Revenue JPY 2.96B · Net JPY 73.0M
    2024-05-10 11:55 UTCEARNINGSQuarterly results — Q1 2024 Revenue JPY 2.73B · Net JPY 152.0M
    2024-02-13 11:30 UTCEARNINGSAnnual results — FY 2024 Revenue JPY 9.87B · Net JPY 681.9M
    2023-02-10 11:30 UTCEARNINGSAnnual results — FY 2023 Revenue JPY 7.89B · Net JPY 454.7M
    2022-02-10 11:30 UTCEARNINGSAnnual results — FY 2022 Revenue JPY 6.02B · Net JPY 240.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage